HC Wainwright & Co. Lowers Astria Therapeutics Rating to Neutral
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 16 2025
0mins
Should l Buy ATXS?
Source: Benzinga
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATXS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATXS
Wall Street analysts forecast ATXS stock price to rise
7 Analyst Rating
0 Buy
7 Hold
0 Sell
Hold
Current: 12.580
Low
13.00
Averages
13.00
High
13.00
Current: 12.580
Low
13.00
Averages
13.00
High
13.00
About ATXS
Astria Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for allergic and immunological diseases. Its lead product candidate is Navenibart, a potential monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, autosomal dominant genetic disorder. Its second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis (AD), an immune disorder associated with loss of skin barrier function and itching. It owns five patent families directed to navenibart. The first patent family is directed to the composition of matter of navenibart and its use in treating various plasma kallikrein associated disorders, including HAE. In the second patent family, it is directed to methods of treating various plasma-kallikrein-associated disorders, including HAE.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BioCryst Pharmaceuticals Faces Dismal Outlook
- Poor Market Performance: BioCryst Pharmaceuticals (NASDAQ:BCRX) has been labeled a consistently underperforming stock by Jim Cramer, suggesting that market expectations for its future performance are low, which could lead to diminished investor confidence.
- New Drug Acquisition: The company finalized a $700 million acquisition of Astria Therapeutics on January 23, adding navenibart, a long-acting therapy for hereditary angioedema, to its portfolio; however, market reactions remain tepid despite this strategic move.
- Therapeutic Expansion: BioCryst focuses on treatments for rare diseases, including an oral medication for hereditary angioedema and injectable flu therapies, yet insufficient market confidence in its drug development may hinder future sales growth.
- Investment Risk Advisory: While BCRX presents investment potential, analysts indicate that certain AI stocks offer greater upside potential and lower downside risk, which may lead investors to consider more attractive investment alternatives.
See More
Halper Sadeh Investigates CSG and Others for Shareholder Rights Violations
- CSG Transaction Investigation: Halper Sadeh LLC is investigating CSG Systems International, Inc.'s sale to NEC Corporation for $80.70 per share in cash, potentially indicating breaches of fiduciary duties that could affect shareholder rights.
- Janus Transaction Scrutiny: The firm is also examining Janus Henderson Group plc's sale to Trian Fund Management and General Catalyst for $49.00 per share in cash, which may impact shareholder interests and rights.
- Clearwater Transaction Focus: Halper Sadeh is looking into Clearwater Analytics Holdings, Inc.'s sale to Permira and Warburg Pincus for $24.55 per share in cash, raising concerns about potential violations of shareholder rights.
- Astria Transaction Analysis: The firm is reviewing Astria Therapeutics, Inc.'s sale to BioCryst Pharmaceuticals, Inc. for $8.55 in cash and 0.59 shares of BioCryst common stock per share, which could affect the rights of Astria shareholders.
See More
Astria Therapeutics to be Sold to BioCryst for $8.55 per Share
- Transaction Investigation: Former Louisiana Attorney General Charles C. Foti and his law firm are investigating the proposed sale of Astria Therapeutics to BioCryst Pharmaceuticals, which involves a compensation of $8.55 in cash and 0.59 shares of BioCryst stock per Astria share, aiming to assess whether this deal undervalues the company.
- Shareholder Rights Concern: KSF is seeking to confirm the adequacy of the transaction process and compensation, emphasizing the importance of protecting shareholder rights by inviting those who believe the deal undervalues the company to discuss their legal options.
- Legal Consultation Services: KSF offers no-obligation legal consultations, encouraging shareholders to contact Managing Partner Lewis S. Kahn, which highlights the firm's commitment to shareholder interests and the pursuit of transaction transparency.
- Market Reaction Potential: The investigation into this transaction could impact shareholder confidence and market performance for Astria, as any findings of unfairness may lead to legal actions that could subsequently affect the company's stock price trajectory.
See More
Astria Therapeutics to be Acquired by BioCryst for $8.55 Cash per Share
- Acquisition Investigation: Halper Sadeh LLC is investigating the transaction between Astria Therapeutics (NASDAQ: ATXS) and BioCryst Pharmaceuticals (NASDAQ: BCRX), which involves $8.55 cash and 0.59 shares of BioCryst common stock per share, potentially indicating breaches of fiduciary duties to shareholders.
- Shareholder Rights Protection: The law firm may seek increased consideration and additional disclosures for shareholders, ensuring their legal rights are protected in the transaction, reflecting a commitment to shareholder interests.
- Green Dot Transaction Review: Green Dot Corporation (NYSE: GDOT) is involved in a sale to Smith Ventures and CommerceOne Financial Corporation for $8.11 in cash and 0.2215 shares of a new publicly traded bank holding company, which is also under investigation by Halper Sadeh LLC.
- United Security Bancshares Deal: United Security Bancshares (NASDAQ: UBFO) is being sold to Community West Bancshares for 0.4520 shares of Community West common stock per share, with Halper Sadeh LLC potentially providing legal support to safeguard shareholder rights.
See More
Avidity Biosciences Acquired by Novartis for $72 per Share
- Acquisition Investigation: Halper Sadeh LLC is investigating Avidity Biosciences, Inc. (NASDAQ:RNA) for its sale to Novartis at $72 per share in cash, potentially violating federal securities laws and fiduciary duties to shareholders.
- Shareholder Rights: The law firm encourages Avidity shareholders to contact them immediately to learn about their rights and options, indicating that shareholder interests may be at risk in the transaction.
- Merger Scrutiny: Halper Sadeh LLC is also examining the merger between Third Coast Bancshares, Inc. (NYSE:TCBX) and Keystone Bancshares, Inc., which may involve fiduciary duty issues affecting shareholders.
- Legal Support: The firm offers legal assistance on a contingency fee basis, ensuring that affected investors can seek increased compensation and disclosures without upfront costs, highlighting their commitment to protecting shareholder rights.
See More
Halper Sadeh LLC Urges ATXS, PCH, RYN Shareholders to Reach Out to the Firm Regarding Their Rights
Investigation of Companies: Halper Sadeh LLC is investigating Astria Therapeutics, PotlatchDeltic Corporation, and Rayonier Inc. for potential violations of federal securities laws and breaches of fiduciary duties related to their proposed transactions.
Details of Transactions: Astria Therapeutics is set to be sold to BioCryst Pharmaceuticals for $8.55 in cash and shares, while PotlatchDeltic will merge with Rayonier, resulting in PotlatchDeltic shareholders owning 46% and Rayonier shareholders owning 54% of the combined company.
Legal Rights for Shareholders: Shareholders of the involved companies are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options regarding the transactions, with the firm offering services on a contingent fee basis.
Firm's Background: Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered significant amounts for defrauded investors.
See More
BioCryst Pharmaceuticals Faces Dismal Outlook
- Poor Market Performance: BioCryst Pharmaceuticals (NASDAQ:BCRX) has been labeled a consistently underperforming stock by Jim Cramer, suggesting that market expectations for its future performance are low, which could lead to diminished investor confidence.
- New Drug Acquisition: The company finalized a $700 million acquisition of Astria Therapeutics on January 23, adding navenibart, a long-acting therapy for hereditary angioedema, to its portfolio; however, market reactions remain tepid despite this strategic move.
- Therapeutic Expansion: BioCryst focuses on treatments for rare diseases, including an oral medication for hereditary angioedema and injectable flu therapies, yet insufficient market confidence in its drug development may hinder future sales growth.
- Investment Risk Advisory: While BCRX presents investment potential, analysts indicate that certain AI stocks offer greater upside potential and lower downside risk, which may lead investors to consider more attractive investment alternatives.
See More
Halper Sadeh Investigates CSG and Others for Shareholder Rights Violations
- CSG Transaction Investigation: Halper Sadeh LLC is investigating CSG Systems International, Inc.'s sale to NEC Corporation for $80.70 per share in cash, potentially indicating breaches of fiduciary duties that could affect shareholder rights.
- Janus Transaction Scrutiny: The firm is also examining Janus Henderson Group plc's sale to Trian Fund Management and General Catalyst for $49.00 per share in cash, which may impact shareholder interests and rights.
- Clearwater Transaction Focus: Halper Sadeh is looking into Clearwater Analytics Holdings, Inc.'s sale to Permira and Warburg Pincus for $24.55 per share in cash, raising concerns about potential violations of shareholder rights.
- Astria Transaction Analysis: The firm is reviewing Astria Therapeutics, Inc.'s sale to BioCryst Pharmaceuticals, Inc. for $8.55 in cash and 0.59 shares of BioCryst common stock per share, which could affect the rights of Astria shareholders.
See More
Astria Therapeutics to be Sold to BioCryst for $8.55 per Share
- Transaction Investigation: Former Louisiana Attorney General Charles C. Foti and his law firm are investigating the proposed sale of Astria Therapeutics to BioCryst Pharmaceuticals, which involves a compensation of $8.55 in cash and 0.59 shares of BioCryst stock per Astria share, aiming to assess whether this deal undervalues the company.
- Shareholder Rights Concern: KSF is seeking to confirm the adequacy of the transaction process and compensation, emphasizing the importance of protecting shareholder rights by inviting those who believe the deal undervalues the company to discuss their legal options.
- Legal Consultation Services: KSF offers no-obligation legal consultations, encouraging shareholders to contact Managing Partner Lewis S. Kahn, which highlights the firm's commitment to shareholder interests and the pursuit of transaction transparency.
- Market Reaction Potential: The investigation into this transaction could impact shareholder confidence and market performance for Astria, as any findings of unfairness may lead to legal actions that could subsequently affect the company's stock price trajectory.
See More
Astria Therapeutics to be Acquired by BioCryst for $8.55 Cash per Share
- Acquisition Investigation: Halper Sadeh LLC is investigating the transaction between Astria Therapeutics (NASDAQ: ATXS) and BioCryst Pharmaceuticals (NASDAQ: BCRX), which involves $8.55 cash and 0.59 shares of BioCryst common stock per share, potentially indicating breaches of fiduciary duties to shareholders.
- Shareholder Rights Protection: The law firm may seek increased consideration and additional disclosures for shareholders, ensuring their legal rights are protected in the transaction, reflecting a commitment to shareholder interests.
- Green Dot Transaction Review: Green Dot Corporation (NYSE: GDOT) is involved in a sale to Smith Ventures and CommerceOne Financial Corporation for $8.11 in cash and 0.2215 shares of a new publicly traded bank holding company, which is also under investigation by Halper Sadeh LLC.
- United Security Bancshares Deal: United Security Bancshares (NASDAQ: UBFO) is being sold to Community West Bancshares for 0.4520 shares of Community West common stock per share, with Halper Sadeh LLC potentially providing legal support to safeguard shareholder rights.
See More
Avidity Biosciences Acquired by Novartis for $72 per Share
- Acquisition Investigation: Halper Sadeh LLC is investigating Avidity Biosciences, Inc. (NASDAQ:RNA) for its sale to Novartis at $72 per share in cash, potentially violating federal securities laws and fiduciary duties to shareholders.
- Shareholder Rights: The law firm encourages Avidity shareholders to contact them immediately to learn about their rights and options, indicating that shareholder interests may be at risk in the transaction.
- Merger Scrutiny: Halper Sadeh LLC is also examining the merger between Third Coast Bancshares, Inc. (NYSE:TCBX) and Keystone Bancshares, Inc., which may involve fiduciary duty issues affecting shareholders.
- Legal Support: The firm offers legal assistance on a contingency fee basis, ensuring that affected investors can seek increased compensation and disclosures without upfront costs, highlighting their commitment to protecting shareholder rights.
See More
Halper Sadeh LLC Urges ATXS, PCH, RYN Shareholders to Reach Out to the Firm Regarding Their Rights
Investigation of Companies: Halper Sadeh LLC is investigating Astria Therapeutics, PotlatchDeltic Corporation, and Rayonier Inc. for potential violations of federal securities laws and breaches of fiduciary duties related to their proposed transactions.
Details of Transactions: Astria Therapeutics is set to be sold to BioCryst Pharmaceuticals for $8.55 in cash and shares, while PotlatchDeltic will merge with Rayonier, resulting in PotlatchDeltic shareholders owning 46% and Rayonier shareholders owning 54% of the combined company.
Legal Rights for Shareholders: Shareholders of the involved companies are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options regarding the transactions, with the firm offering services on a contingent fee basis.
Firm's Background: Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered significant amounts for defrauded investors.
See More
